Skip to main navigation menu Skip to main content Skip to site footer

Clinical pathological characteristics and survival of patients with breast cancer attended at IMAT (Montería).

Características clínico-patológicas y sobrevida de las pacientes con cáncer de mama atendidas en el Instituto Médico de Alta Tecnología (IMAT) (Montería).




Section
Original articles

How to Cite
Clinical pathological characteristics and survival of patients with breast cancer attended at IMAT (Montería).
Rev. colomb. hematol. oncol. [Internet]. 2017 Oct. 1 [cited 2024 Dec. 22];4(1):26-30. Disponible en: https://doi.org/10.51643/22562915.162

Dimensions
PlumX
José Lobatón
    Manuel González
      Fernando Oviedo
        Marco Torregroza
          Sandra Aruachán

            Breast cancer is a public health problem that deserves special attention because of its incidence and its profound social impact because it affects women, the fundamental axis of the modern family. Objective: The aim of this study was to describe clinical-pathological characteristics and survival rate of patients with breast cancer treated at IMAT Oncomédica. Methods: Descriptive, retrospective observational study of 506 patients with breast cancer, where socioeconomic, histological variables, hormone receptor and HER2 expression, treatments and relapses were analyzed. Results: The mean age at diagnosis was 54 years. The predominant histological subtype was ductal and most patients had an early disease. The 5-year overall survival rate in all patients in the study was 77.6%. The pathological response rate to neoadjuvant chemotherapy was 11% in all patients. The 6-year overall survival rate in patients receiving neoadjuvant chemotherapy was greater in those who achieved complete pathologic response (74.4%) versus those who did not achieve complete pathologic response (62.1%) (p = 0.044). Conclusions: This research was carried out at IMAT, a cancer reference center for Córdoba. This is the first study to determine the clinical and pathological characteristics of people with breast cancer in this region, with results of overall survival rate similar to Latin American countries and close to the rates of Europe and the United States.


            Article visits 370 | PDF visits 288


            1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C. Globocan 2012 v.1.0, Cancer incidence and mortality worldwide: IARC Cancer Base Nº 11 [internet]. 2013 [citado 2017]. Disponible en: http://www.globocan.airc.fr
            2. DeVita V, Lawrence T, Rosenberg S. Cancer principles & practice of clinical oncology. 9th ed. Philadelphia: Wolters Kluwer; 2011.
            3. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013;139(2):539-52.
            4. Coronato S, Laguens G, Spinelli O, Girolamo W. Marcadores tumorales en cáncer de mama. Medicina 2002;62:73-82.
            5. Pardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia 2007-2011. 1ª ed. Instituto Nacional de Cancerología; 2012.
            6. Nadji M, Gómez-Fernández C, Ganjei-Azar P, Morales A. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123(1):21-7.
            7. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26(14):2373-8.
            8. Angarita F, Acuña S, Torregrosa L, Tawil M, Ruiz A. Presentación inicial de las pacientes con diagnóstico de cáncer de seno en el Centro Javeriano de Oncología, Hospital Universitario San Ignacio. Revista Colombiana de Cirugía 2010;25(1):19-26.
            9. Martin-Castillo B, Lopez-Bonet E, Cuyas E, Viñas G, Pernas S, Dorca J, et al. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget 2015;6(32):32317-38.
            10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
            11. Kaufmann M, Hortobagyi G, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006;24(12):1940-9.
            Sistema OJS 3.4.0.7 - Metabiblioteca |